What ACT Capital Management does

ACT Capital Management, LLC is a privately held, SEC-registered investment adviser (CRD 307272) founded in 2003 and headquartered at 100 W. Lancaster Avenue, Suite 110, Wayne, Pennsylvania. The firm manages private hedge fund capital on behalf of institutional investors and qualified high-net-worth individuals, employing a long-biased long/short strategy concentrated in growth equities with a long-term time horizon.

The firm's investment focus is on publicly traded U.S. equities and select small private equity investments in companies with disruptive products, ideas, and innovation. Sector emphasis is BioPharma-centric and spans biopharmaceuticals/biotechnology/life sciences, medical technology and diagnostics, and artificial intelligence, cloud computing, and SaaS. The strategy uses concentrated positions in top ideas combined with extensive option writing to hedge, acquire, or exit positions, with a stated bullish bias toward medical and technological advancement.

ACT is a two-person operating firm. Amir L. Ecker serves as Founder, Managing Member, and Portfolio Manager with 30+ years of investment experience and 20+ years running the ACT strategy, while Fayth R. Ecker serves as Chief Compliance Officer, Fund Manager, and Member. Revenue is generated through management and performance fees on the single hedge fund vehicle, distributed exclusively through direct, relationship-based private placements with no retail or intermediary channel. There is no evidence of a technology platform, app, or API product; the firm's intellectual capital is its portfolio management expertise.

Name

ACT Capital Management

Legal name

ACT Capital Management, LLC

Website

https://actcapitalmanagement.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

ACT Capital Management is a privately held, SEC-registered investment adviser founded in 2003 in Wayne, Pennsylvania, managing private hedge fund capital for institutional and high-net-worth investors through a concentrated, long-biased long/short strategy focused on disruptive growth equities in biopharma, medtech, and AI/cloud/SaaS sectors.

Ownership category

akta.pro rank

Product category

Hedge Fund Management

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Equity Long/Short (FSAHAAAC)

akta.pro secondary industry

Sector/Thematic Equity (Active) (FSAAAIAG)

Keywords

• Hedge fund management
• Growth equity investing
• Long-short strategy
• Biotech investment
• Alternative asset management

Headquarters

HQ city

Wayne

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Compliance or Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Hedge Fund Management: Generates revenue through management fees and performance fees from managing private hedge funds. The firm manages concentrated positions in growth stocks with a long-term time horizon and employs extensive option writing strategies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

ACT Capital Management manages private hedge fund portfolios for institutional and qualified high-net-worth investors, primarily investing in publicly traded U.S. equities with small private equity investments. The strategy employs concentrated positions in top ideas across biopharmaceuticals, biotechnology, life sciences, medical technology, diagnostics, AI, cloud, and SaaS, using a long-biased long/short approach with extensive option writing to hedge, acquire, or exit positions.

Product overview

ACT Capital Management offers a single unified investment management service for private hedge funds. The core offering consists of portfolio management focused on publicly traded U.S. equities and small private equity investments, with a long-term time horizon and a BioPharma-centric, long-biased long/short strategy. The firm targets growth stocks with disruptive products, ideas, and innovation across biopharmaceuticals, biotechnology, life sciences, medical technology, diagnostics, AI, cloud, and SaaS sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Private Hedge Fund Investment Management Portfolio management services for private hedge funds, primarily investing in publicly traded U.S. equities with small private equity investments. The strategy holds concentrated long-term positions in top ideas, employs a BioPharma-centric long-biased long/short structure, and uses extensive option writing to hedge, acquire, or exit positions, targeting institutional and qualified high-net-worth investors.

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves3 records

Expansion highlights1 record

Broad incumbents

• BlackRock: Global asset manager with active equity and alternative investment capabilities across multiple sectors. Comparable as a broad incumbent operating in the same overall asset management space, but not focused on ACT's specific biotech/AI niche.
• Janus Henderson Investors: Large diversified asset manager offering long/short and long-only equity strategies including sector-focused mandates. Comparable as a broad incumbent offering overlapping capabilities, but not specialist in ACT's niche sectors.

Direct peers

• Baker Bros. Advisors: Long-standing biotech specialist running concentrated, long-biased public-equity and private-equity strategies. Highly comparable to ACT's concentrated, sector-focused equity model in life sciences.
• RA Capital Management: Healthcare- and biotech-focused long/short fund with deep domain expertise and concentrated positions in disruptive life sciences companies. Directly comparable to ACT's biotech/medtech-focused long/short strategy.
• Altimeter Capital: Concentrated, long-duration technology and growth-equity investor with public-equity exposure to AI and cloud disruptors. Comparable to ACT's high-conviction, growth-stock-focused approach.
• EcoR1 Capital: Biotech-focused long/short equity fund investing in disruptive therapeutic platforms. Comparable to ACT's concentrated, sector-specialist long/short approach in biopharmaceuticals.
• Perceptive Advisors: Biotech and healthcare-focused investment firm running long/short equity and credit strategies. Closely comparable to ACT's sector-focused, long-biased approach in life sciences and medical technology.
• OrbiMed Advisors: Healthcare-dedicated investment firm managing public-equity and private-equity strategies across biotech, medtech, and diagnostics. Comparable to ACT in sector specialization and long-term investment horizon.
• Cormorant Asset Management: Healthcare and biotech-focused long/short equity manager with concentrated positions in disruptive life sciences companies. Closely comparable to ACT's biotech-centric, long-biased strategy.
• Coatue Management: Technology-focused long/short equity manager with significant exposure to AI, cloud, and SaaS names. Comparable to ACT's AI/cloud/SaaS sector concentration and growth-oriented long/short structure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ACT Capital Management